(R)-八氢-1H-吲哚-2-羧酸 | 108507-42-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (R)-八氢-1H-吲哚-2-羧酸
• 英文名称: (2R,3aR,7aR)-Octahydro-1H-indole-2-carboxylic acid
• 英文别名: (2R,3aR,7aR)-2,3,3a,4,5,6,7,7a-octahydro-1H-indole-2-carboxylic acid
• CAS: 108507-42-2
• 化学式: C₉H₁₅NO₂
• 分子量: 169.224
• InChiKey: CQYBNXGHMBNGCG-BWZBUEFSSA-N

物化性质

• 沸点：
  318.6±25.0 °C(Predicted)
• 密度：
  1.135±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  56.7
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  吲哚-2-羧酸乙酯 在 Rh on carbon 盐酸 、 sodium hydroxide 、 氢气 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 11.0h， 生成 (R)-八氢-1H-吲哚-2-羧酸
  参考文献：
  名称：

  新型有效的含有饱和双环氨基酸的血管紧张素转化酶抑制剂的合成与构效关系。

  摘要：

  描述了一系列新型的，有效的血管紧张素转化酶（ACE）抑制剂的合成，这些抑制剂含有饱和的双环氨基酸代替脯氨酸。八氢吲哚-2-羧酸，八氢异吲哚-1-羧酸和八氢-3-氧代异吲哚-1-羧酸可取代巯基和非巯基ACE抑制剂中的脯氨酸，从而在体外和体内均产生与卡托普利和依那普利等效的化合物体内。讨论了构效关系。化合物11a（CI-907，吲哚普利）已进入临床评估阶段。

  DOI：

  10.1021/jm00389a006

文献信息

• [EN] [B]-FUSED BICYCLIC PROLINE DERIVATIVES AND THEIR USE FOR TREATING ARTHRITIC CONDITIONS<br/>[FR] DERIVES BICYCLIQUES [B]-FUSIONNES DE PROLINE ET LEUR UTILISATION POUR TRAITER DES ETATS ARTHRITIQUES
  申请人：WARNER LAMBERT CO

  公开号：WO2004092132A1

  公开（公告）日：2004-10-28

  The invention relates to a compound which is [b]-fused bicyclic proline derivative, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the salt thereof, and methods of treating diseases, including, but not limited to, methods of preventing or inhibiting joint cartilage damage and preventing or treating diseases characterized by joint cartilage damage, joint inflammation, or joint pain. The [b]-fused bicyclic proline derivatives are compounds of Formula I as described above. Diseases characterized by joint cartilage damage or joint pain include, for example, osteoarthritis and rheumatoid arthritis. Rheumatoid arthritis is also characterized by joint inflammation. This invention also relates to methods of synthesizing and preparing the [b]-fused bicyclic proline derivatives, or a pharmaceutically acceptable salt thereof.

  该发明涉及一种[b]-融合双环脯氨酸衍生物，或其药用盐；包括该化合物或其盐的药物组合物；以及治疗疾病的方法，包括但不限于预防或抑制关节软骨损伤，预防或治疗以关节软骨损伤、关节炎或关节疼痛为特征的疾病的方法。[b]-融合双环脯氨酸衍生物是上述化合物的I式化合物。以关节软骨损伤或关节疼痛为特征的疾病包括骨关节炎和类风湿性关节炎。类风湿性关节炎也以关节炎为特征。该发明还涉及合成和制备[b]-融合双环脯氨酸衍生物或其药用盐的方法。
• [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions
  申请人：Barvian C. Nicole

  公开号：US20050143427A1

  公开（公告）日：2005-06-30

  This invention relates to a compound which is [b]-fused bicyclic proline derivative, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the salt thereof, and methods of treating diseases, including, but not limited to, methods of preventing or inhibiting joint cartilage damage and preventing or treating diseases characterized by joint cartilage damage, joint inflammation, or joint pain. The [b]-fused bicyclic proline derivatives are compounds of Formula I as described above. Diseases characterized by joint cartilage damage or joint pain include, for example, osteoarthritis and rheumatoid arthritis. Rheumatoid arthritis is also characterized by joint inflammation. This invention also relates to methods of synthesizing and preparing the [b]-fused bicyclic proline derivatives, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种[b]-融合的双环脯氨酸衍生物，或其药学上可接受的盐；包括该化合物或其盐的制药组合物，以及治疗疾病的方法，包括但不限于预防或抑制关节软骨损伤和预防或治疗以关节软骨损伤、关节炎或关节疼痛为特征的疾病的方法。[b]-融合的双环脯氨酸衍生物是如上所述的式I的化合物。以关节软骨损伤或关节疼痛为特征的疾病包括骨关节炎和类风湿性关节炎等。类风湿性关节炎也以关节炎为特征。本发明还涉及合成和制备[b]-融合的双环脯氨酸衍生物或其药学上可接受的盐的方法。
• Novel method for preparation of crystalline perindopril erbumine
  申请人：Singh Pal Girij

  公开号：US20070149604A1

  公开（公告）日：2007-06-28

  A process for preparation of crystalline perindopril erbumine of formula (II) which exhibits the X-ray (powder) diffraction pattern like that shown in FIG. 2 The process comprises reacting a solution of perindopril of formula (I), in a solvent selected from N,N-dimethylformamide, dimethyl acetals of lower aliphatic aldehydes, dimethyl ketals of lower aliphatic ketones and 1,2-dialkoxyethane with tertiary butylamine and crystallization of the erbumine salt thus obtained by heating the reaction mixture to reflux, filtering hot, cooling gradually to 20° C. to 30° C., and further cooling to 0° C. to 15° C. for 30 minutes to 1 hour and finally filtering off and drying the crystals.

  一种制备式（II）晶体型的依普利酸厄贝林的方法，其展现出类似于图2所示的X射线（粉末）衍射图谱。该方法包括在从N,N-二甲基甲酰胺、低级脂肪醛的二甲基缩醛、低级脂肪酮的二甲基缩酮和1,2-二烷氧基乙烷中选择的溶剂中反应式（I）的依普利酸溶液，与叔丁胺反应，并通过将反应混合物加热至回流，过滤热，逐渐冷却至20°C至30°C，然后进一步冷却至0°C至15°C，保持30分钟至1小时，最后过滤并干燥晶体来结晶得到厄贝林盐。
• TFPI inhibitors and methods of use
  申请人：BAXALTA GMBH

  公开号：US10201586B2

  公开（公告）日：2019-02-12

  The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.

  本发明提供了结合组织因子途径抑制剂（TFPI）的肽，包括TFPI抑制肽及其组合物。这些肽可用于抑制 TFPI、增强凝血因子缺乏症患者的凝血酶形成、增加患者的血凝块形成、治疗患者的血液凝固障碍、纯化 TFPI 以及鉴定 TFPI 结合化合物。
• [EN] PROCESS FOR THE PREPARATION OF PERINDOPRIL<br/>[FR] PROCEDE ET PRODUIT
  申请人：CIPLA LTD

  公开号：WO2004099138A3

  公开（公告）日：2004-12-23